Which company develops and produces Everolimus?

Everolimus (Everolimus) is a drug developed and produced by the Swiss pharmaceutical giant Novartis (Novartis). Novartis is one of the world's leading pharmaceutical companies, recognized for its outstanding contributions to pharmaceutical research and innovation.

Everolimus is an immunosuppressant that belongs to the TOR (targeting of rapamycinase) inhibitor drug class. This drug inhibits cell proliferation and growth by interfering with the TOR signaling pathway, thereby preventing organ rejection after organ transplantation and treating certain types of cancer.

Novartis is a pharmaceutical company with a long history and strong strength, with an extensive R&D network and production bases around the world. The company is not only committed to developing innovative drugs, but also provides a range of solutions in the medical field, covering all aspects from clinical trials to patient care.

The research and development of everolimus marks Novartis’ deep strength and innovation capabilities in the field of medical science. The advent of this drug provides an important tool for clinical treatment, especially in the fields of organ transplantation and cancer treatment. Novartis's mission is to provide better healthcare solutions to patients around the world through continuous scientific research and innovation. The successful development and application of everolimus is one of the concrete manifestations of this mission.

Everolimus has been approved for marketing in my country, and has been included in the national medical insurance. The price is about 4000~5000 yuan. It takes about 2 boxes of everolimus per month. For specific prices and medical insurance reimbursement policies, please consult the local hospital pharmacy or medical insurance bureau. The cheaper ones abroad are mainly Indian generic drugs, the price is around 700~1,500yuan, and the ingredients of the drugs are basically the same as those in China.